Literature DB >> 4091527

Antimalarial activities and subacute toxicity of RC-12, a 4-amino-substituted pyrocatechol.

L H Schmidt, R N Rossan, R Fradkin, R Sullivan, W Schulemann, L Kratz.   

Abstract

RC-12 [1,2-dimethoxy-4-(bis-diethylaminoethyl)-amino-5-bromobenzene] was evaluated for prophylactic, radical curative, and suppressive activities against infections with Plasmodium cynomolgi and subacute toxicity in rhesus monkeys. Applied as a prophylactic agent, RC-12, administered in doses of 6.25 to 25.0 mg/kg daily throughout the incubation period, provided near-complete to complete protection against 10(5) to 10(6) times the minimum infective dose of sporozoites. Applied as a suppressive agent, daily doses of 100.0 mg of RC-12 per kg did not eradicate blood schizonts regularly; hence, the need for concomitant administration of a blood schizonticide, such as chloroquine, in assessments of radical curative activity. In such appraisals, daily doses of 6.25 to 25.0 mg of RC-12 per kg for 14 days, in combination with 2.5 mg of chloroquine per kg daily for 7 days, effected cure of 69 and 93% of established infections, respectively. The curative activity of RC-12 was related to the total dose and could be achieved with a regimen as brief as 4 days. With respect to outward expressions of toxicity, daily doses of 50.0 mg/kg or lower for 15 to 225 days evoked no reactions. Doses of 100.0 or 200.0 mg/kg, scheduled for 15 days, evoked convulsions and depression and were, respectively, lethal to 4 of 17 and 7 of 7 recipients. Doses of 25.0 mg/kg or lower evoked no discrete reactions. Doses of 50.0 mg/kg and higher evoked hepatomegaly, vacuolation of hepatocytes, and elevations of glutamic oxalacetic and glutamic pyruvic transferase activities in serum, reactions related in intensity to dose but not duration of dosage.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4091527      PMCID: PMC176344          DOI: 10.1128/AAC.28.5.612

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  22 in total

1.  PROTHROMBIN: ANALYTICAL AND CLINICAL ASPECTS. COMPARISON OF THE ONE- AND TWO-STAGE METHODS.

Authors:  A J QUICK; C V HUSSEY; M GEPPERT
Journal:  Am J Med Sci       Date:  1963-11       Impact factor: 2.378

2.  A spectrophotofluorometric study of organic compounds of pharmacological interest.

Authors:  S UDENFRIEND; D E DUGGAN; B M VASTA; B B BRODIE
Journal:  J Pharmacol Exp Ther       Date:  1957-05       Impact factor: 4.030

3.  Mass antimalarial therapy in veterans returning from Korea.

Authors:  C P ARCHAMBEAULT
Journal:  J Am Med Assoc       Date:  1954-04-24

4.  The chemotherapy of rodent malaria, XXIII Causal prophylaxis, part II: Practical experience with Plasmodium yoelii nigeriensis in drug screening.

Authors:  W Peters; E E Davies; B L Robinson
Journal:  Ann Trop Med Parasitol       Date:  1975-09

5.  Assessment of causal prophylactic activity in Plasmodium berghei yoelii and its value for the development of new antimalarial drugs.

Authors:  E Fink
Journal:  Bull World Health Organ       Date:  1974       Impact factor: 9.408

6.  The antimalarial properties of 2, 4-diamino-5-p-chlorophenyl-6-ethylpyrimidine, daraprim.

Authors:  L H SCHMIDT; C S GENTHER
Journal:  J Pharmacol Exp Ther       Date:  1953-01       Impact factor: 4.030

7.  The problem of vivax malaria in Vietnam returnees. II. Malaria chemoprophylaxis survey.

Authors:  G Skrzypek; O Barrett
Journal:  Mil Med       Date:  1968-06       Impact factor: 1.437

8.  Studies on the prophylactic and radical curative activity of RC-12 against Plasmodium cynomolgi in Macaca mulatta.

Authors:  T M Sodeman; P G Contacos; W E Collins; C S Smith; J R Jumper
Journal:  Bull World Health Organ       Date:  1972       Impact factor: 9.408

9.  Quantitative aspects of pyrimethamine-sulfonamide synergism.

Authors:  L H Schmidt; J Harrison; R N Rossan; D Vaughan; R Crosby
Journal:  Am J Trop Med Hyg       Date:  1977-09       Impact factor: 2.345

10.  Appraisals of compounds of diverse chemical classes for capacities to cure infections with sporozoites of Plasmodium cynomolgi.

Authors:  L H Schmidt
Journal:  Am J Trop Med Hyg       Date:  1983-03       Impact factor: 2.345

View more
  4 in total

Review 1.  A pre-emptive strike against malaria's stealthy hepatic forms.

Authors:  Dominique Mazier; Laurent Rénia; Georges Snounou
Journal:  Nat Rev Drug Discov       Date:  2009-11       Impact factor: 84.694

Review 2.  Killing the hypnozoite--drug discovery approaches to prevent relapse in Plasmodium vivax.

Authors:  Brice Campo; Omar Vandal; David L Wesche; Jeremy N Burrows
Journal:  Pathog Glob Health       Date:  2015-04-18       Impact factor: 2.894

3.  Why functional pre-erythrocytic and bloodstage malaria vaccines fail: a meta-analysis of fully protective immunizations and novel immunological model.

Authors:  D Lys Guilbride; Pawel Gawlinski; Patrick D L Guilbride
Journal:  PLoS One       Date:  2010-05-19       Impact factor: 3.240

4.  Metabolic, Pharmacokinetic, and Activity Profile of the Liver Stage Antimalarial (RC-12).

Authors:  Yuxiang Dong; Yogesh Sonawane; Steven P Maher; Anne-Marie Zeeman; Victor Chaumeau; Amélie Vantaux; Caitlin A Cooper; Francis C K Chiu; Eileen Ryan; Jenna McLaren; Gong Chen; Sergio Wittlin; Benoît Witkowski; François Nosten; Kamaraj Sriraghavan; Dennis E Kyle; Clemens H M Kocken; Susan A Charman; Jonathan L Vennerstrom
Journal:  ACS Omega       Date:  2022-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.